Moderna Therapeutics Forms Technology Advisory Board for Manufacturing
Moderna Therapeutics, a developer of proprietary messenger RNA (mRNA) therapeutics to enable the in vivo production of therapeutic proteins, has formed a technology advisory board to advise the company of building a GMP manufacturing capabilities for its own clinical programs and for organizations which it has strategic agreements. These include AstraZeneca, Alexion Pharmaceuticals and the Defense Advanced Research Projects Agency, part of the US Department of Defense.
The board will focus initially on scaling the production of mRNA from micrograms to kilograms to full commercial scale. “Moderna's strategy is to own its R&D technology and its API GMP manufacturing,” said Stéphane Bancel, president and founding CEO of Moderna, in a company statement.
Source: Moderna Therapeutics
